NOVN.CH

97.32

-2.25%↓

NOVN.CH

97.32

-2.25%↓

NOVN.CH

97.32

-2.25%↓

NOVN.CH

97.32

-2.25%↓

NOVN.CH

97.32

-2.25%↓

Search

Bachem Holding AG

Avatud

SektorTervishoid

50.9 -1.83

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

49.86

Max

52.1

Põhinäitajad

By Trading Economics

Sissetulek

36M

Müük

240M

P/E

Sektori keskmine

32.375

63.778

Dividenditootlus

1.58

Kasumimarginaal

15.046

Töötajad

2,207

EBITDA

55M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+30.12% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.58%

2.39%

Turustatistika

By TradingEconomics

Turukapital

3.9B

Eelmine avamishind

52.73

Eelmine sulgemishind

50.9

Uudiste sentiment

By Acuity

50%

50%

173 / 386 Pingereas Healthcare

Bachem Holding AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. dets 2024, 11:00 UTC

Market Talk

Bachem Has Challenging Years Ahead With Strong Capital Expenditure -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Bachem Holding AG Prognoos

Hinnasiht

By TipRanks

30.12% tõus

12 kuu keskmine prognoos

Keskmine 67.4 CHF  30.12%

Kõrge 78 CHF

Madal 55 CHF

Põhineb 5 Wall Streeti analüütiku instrumendi Bachem Holding AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

2

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

173 / 386 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.